{"slug":"ac-sdkp","seoKey":"acsdkp","inn":"goralatide","displayName":"Ac-SDKP","codes":[],"synonyms":["AcSDKP","goralatide","seraspenide","N-acetyl-seryl-aspartyl-lysyl-proline","N-acetyl-Ser-Asp-Lys-Pro","Ac-Ser-Asp-Lys-Pro","thymosin beta-4 fragment 1-4"],"legalClass":"research_chemical","identifiers":{"cas":"120081-14-3","pubchemCid":65938,"unii":"H041538E9P","inchikey":"HJDRXEQUFWLOGJ-AJNGGQMLSA-N","chemblId":"CHEMBL2104460","wikidataQid":"Q27279387","formula":"C20H33N5O9","molecularWeight":487.5,"sequence":"Ac-SDKP"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved, now or ever. On 2026-09-23 the agency's databases of approved drugs, labels, the national drug code directory and enforcement reports, together with the structured label archive, returned no match for goralatide, seraspenide or SDKP; a control query for captopril in the same run returned results. The substance is not on the list of bulk drug substances that may present significant safety risks in compounding (where TB-500 is), and it has not been nominated for either compounding pathway.","source":"https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:goralatide"},{"market":"EU","status":"not_approved","note":"Not approved: the agency's official medicines report dated 2026-09-23 contains no match for goralatide, seraspenide or SDKP, while a control term in the same dataset returned matches. The substance has an entry in the EU substance dictionary; such a code only documents that the substance exists and is not an authorisation.","source":"https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx"},{"market":"DE","status":"not_approved","note":"Not approved: no centralised EU authorisation exists, and no national authorisation is apparent. The national medicines registers could not be queried by machine, so this rests on the EU finding. Separately, the annex to the anti-doping act lists thymosin beta-4 and its derivatives and states that derivatives are included; Ac-SDKP is not named, and whether a natural fragment counts as a derivative under criminal law has not been tested in court.","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Not approved: the Electronic Medicines Compendium returned no results for goralatide on 2026-09-23, while a control query for captopril in the same run returned products. The regulator's own product register was not queried, because it is a script-driven application that could not be evaluated server-side.","source":"https://www.medicines.org.uk/emc/search?q=goralatide"},{"market":"AU","status":"not_approved","note":"Not approved: no medicine containing the substance is authorised, and it is not named in the Poisons Standard; the full text of the June 2026 edition was searched on 2026-09-23 for goralatide, SDKP and seraspenide with no match, while the control entries for thymosin beta-4 and TB-500 were found in the same document. The register of therapeutic goods was not queried directly. Separate from approval, one question of interpretation is open: thymosin beta-4 sits in Schedule 4 and in Appendix D, clause 5, which restricts possession, and schedule entries cover derivatives by default, decided on a balanced consideration. Whether Ac-SDKP counts as such a derivative has not been officially determined; under the stricter reading it would be prescription-only with restricted possession, like TB-500.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query of the drug product database returned an empty result on 2026-09-23. A control query for captopril in the same run returned several ingredient rows, so the negative finding is sound.","source":"https://health-products.canada.ca/api/drug/activeingredient/?lang=en&type=json&ingredientname=goralatide"},{"market":"CH","status":"not_approved","note":"Not approved: the regulator's extended list of authorised medicinal products, retrieved on 2026-09-23, has no match for goralatide, seraspenide, SDKP or thymosin. Control terms in the same dataset returned matches (ramipril, enalapril, semaglutide).","source":"https://www.swissmedic.ch/dam/swissmedic/de/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/Erweiterte_Arzneimittelliste%20HAM.xlsx"}],"devStage":"discontinued","strongestEvidence":"observational","wada":{"status":"prohibited","section":"S2.3","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://www.wikidata.org/wiki/Q27279387","https://pubchem.ncbi.nlm.nih.gov/compound/65938"],"lastVerified":"2026-09-24","version":"1.0","published":true,"locale":"en","title":"Ac-SDKP: what the studies show, status and safety","summary":"Ac-SDKP is a tiny peptide of four building blocks that the body cuts from the protein thymosin β4 and that the enzyme ACE breaks down again. It is sold online as a TB-500 fragment, but that name is wrong. TB-500 copies a different stretch of the same protein, and the two do not overlap. In people, Ac-SDKP has mainly been studied as a blood marker that rises about 5.5-fold when ACE is blocked. Every effect of giving it comes from animals and cells, and no country has approved it.","updated":"2026-09-24","url":"https://mypep.app/peptides/ac-sdkp"}